NCT04371796View on ClinicalTrials.gov

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

PHASE2UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

May 10, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

December 30, 2021

Conditions

Lung DiseasesNeoplasmsRespiratory Tract DiseasesThoracic NeoplasmsNon-small-cell Lung Cancer

Interventions

DRUG

Sintilimab injection

Sintilimab injection 200mg, 2cycles of treatment before surgery

Sponsors

Collaborators (1)

Innovent Biologics, Inc.

All Listed Sponsors

collaborator

Innovent Biologics, Inc.

OTHER

lead

Sichuan Cancer Hospital and Research Institute

OTHER